TCF25 as a Key Nutrient Sensor: Linking Lysosomal Acidification to Cell Death Under Glucose Starvation

Study Background and Research Question

Cellular adaptation to nutrient stress is a fundamental process in physiology and disease. Glucose, as the primary energy substrate, is essential for ATP production and biosynthesis. When glucose availability drops, cells activate compensatory mechanisms, such as autophagy, to maintain energy balance and survive adverse conditions. However, prolonged or severe glucose deprivation can tip the balance toward cell death, contributing to tissue injury seen in metabolic and ischemic diseases. While regulators like AMPK are established mediators of metabolic adaptation, the precise orchestration of autophagy, lysosomal function, and cell fate during glucose starvation remains incompletely understood (Ren et al., 2025).

Key Innovation from the Reference Study

The study by Ren et al. provides a pivotal advance by identifying Transcription Factor 25 (TCF25) as a novel nutrient sensor that links glucose deprivation to lysosomal acidification and cell death. Using a genome-wide CRISPR-Cas9 screen, the authors discovered that TCF25 is necessary for glucose-starvation-induced cell death. Mechanistically, TCF25 enhances lysosomal acidification by promoting vacuolar-type H⁺-ATPase (V-ATPase) activity, thus facilitating autophagy and metabolic adaptation under nutrient stress (Ren et al., 2025).

Methods and Experimental Design Insights

The research employed a systematic CRISPR-Cas9 knockout screen in mammalian cells subjected to glucose starvation. Genes that, when disrupted, conferred resistance to cell death were prioritized for deeper analysis. Among these, lysosomal pathway genes were highly represented, leading the authors to focus on TCF25. Functional assays included:

• Assessment of cell viability and death under glucose deprivation with or without TCF25 deletion.
• Measurement of lysosomal acidification using pH-sensitive dyes and tracking autophagic flux.
• Genetic and pharmacological perturbation of V-ATPase activity.
• Investigation of ferritinophagy (selective autophagic degradation of ferritin) and its contribution to lysosome-dependent cell death (LDCD).
• In vivo validation in a mouse model of hepatic ischemia-reperfusion injury (IRI).

These approaches provided an integrated view of how TCF25 modulates lysosomal functions in the context of metabolic stress.

Core Findings and Why They Matter

The central discovery is that TCF25 is indispensable for lysosomal acidification and consequent autophagic adaptation under glucose scarcity. Specifically:

• TCF25 enhances V-ATPase function: TCF25 upregulates or stabilizes components of the V-ATPase complex, resulting in improved proton transport and acidification of lysosomes (Ren et al., 2025).
• Promotes autophagy for energy maintenance: Enhanced lysosomal acidification supports efficient fusion of autophagosomes and degradation of cellular cargo, crucial for survival during early phases of glucose deprivation.
• Triggers lysosome-dependent cell death under prolonged starvation: Persistent TCF25-mediated activation of ferritinophagy increases lysosomal membrane permeability (LMP), ultimately leading to LDCD. Disruption of TCF25 or V-ATPase protects cells from this fate.
• In vivo relevance: TCF25 deficiency in mice confers resistance to hepatic injury following ischemia-reperfusion, suggesting translational potential for targeting this axis in metabolic or ischemic pathologies.

These results highlight the dual role of TCF25: promoting adaptation under transient stress but predisposing cells to death upon sustained deprivation. This axis provides a mechanistic explanation for the fine balance between survival and death in nutrient-stressed tissues and suggests that modulation of lysosomal acidification could offer therapeutic leverage points.

Comparison with Existing Internal Articles

This new evidence resonates with the role of V-type H⁺-ATPase inhibitors, such as Concanamycin A, described in several internal resources (Resource 1; Resource 2; Resource 3). These articles characterize Concanamycin A as a potent and selective V-type H⁺-ATPase inhibitor that blocks endosomal acidification and induces apoptosis in tumor cells, thereby providing a critical tool for dissecting V-ATPase-mediated pathways in cancer biology research.

While the reference study focuses on nutrient sensing and metabolic adaptation, internal articles detail the application of V-ATPase inhibitors for modulating apoptosis and invasion in tumor models. Both research threads converge on the centrality of V-ATPase in controlling lysosomal pH and downstream cellular outcomes. The reference paper adds an upstream regulatory layer (TCF25), while internal resources emphasize practical workflows and pharmacological tools to manipulate this pathway for research purposes.

For instance, internal protocols outline how nanomolar concentrations of Concanamycin A efficiently disrupt endosomal acidification, paralleling the genetic disruption of V-ATPase in the reference study (Resource 2).

Limitations and Transferability

Despite its mechanistic depth, the study by Ren et al. is primarily based on in vitro cellular models and a single in vivo context (hepatic IRI). The generalizability of TCF25's role across other tissues, cell types, or metabolic stresses requires further investigation. Moreover, the long-term effects of manipulating the TCF25-V-ATPase axis—especially in complex disease settings—remain to be clarified.

Pharmacological inhibition of V-ATPase, as achieved with Concanamycin A, is a valuable research approach but may have broader effects beyond the TCF25-mediated pathway. Thus, results from such interventions should be interpreted in the context of potential off-target or pleiotropic consequences (Resource 3).

Protocol Parameters

• assay: V-ATPase inhibition | value_with_unit: 10 nM IC₅₀ | applicability: tumor cell models, lysosomal acidification studies | rationale: Achieves potent and selective inhibition of proton transport | source_type: product_spec
• assay: Lysosomal acidification measurement | value_with_unit: pH-sensitive dye, 20 nM Concanamycin A, 60 min treatment | applicability: validation of V-ATPase function | rationale: Standard protocol to visualize inhibition of acidification | source_type: workflow_recommendation
• assay: Apoptosis induction in tumor cells | value_with_unit: 20 nM, 60 min | applicability: prostate, colorectal, cervical cancer cell lines | rationale: Effective for studying apoptosis and invasion pathways | source_type: product_spec

Research Support Resources

To experimentally recapitulate or extend findings on V-ATPase activity and lysosomal acidification, researchers can utilize Concanamycin A (SKU A8633), a well-characterized, nanomolar-range V-type H⁺-ATPase inhibitor. This reagent is supplied as a 1 mg/mL solution and is widely adopted in cancer biology research for studying inhibition of endosomal acidification, apoptosis induction in tumor cells, and invasion inhibition in prostate cancer models (source: product_spec). For optimal results, follow recommended storage and handling protocols, and adjust concentration and treatment duration to the specific cell model and assay design.